Truist initiated coverage of Inventiva (IVA) with a Buy rating and $13 price target Lead asset lanifibranor has a unique mechanism and profile among metabolic dysfunction-associated steatohepatitis therapies in development that could make it “an ideal choice” for a niche group of MASH patients with diabetes, the analyst tells investors. Near-term Phase 3 data due in the second half of the year “could result in up to +100% upside from current levels,” contends the analyst, who estimates base case third-line use in MASH F2/F3 supports $2.3B worldwide peak adjusted revenue.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IVA:
- Inventiva: Strong Balance Sheet and Late-Stage MASH Candidate Lanifibranor Drive Compelling Buy Rating
- Inventiva Posts Preliminary 2025 Results and Extends Cash Runway After Major U.S. Offering
- 3 Best Stocks to Buy Today, 1/28/2026, According to Top Analysts
- Inventiva initiated with an Overweight at Barclays